Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors
Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier R, Richards D, Wang Y. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scandinavian Journal Of Gastroenterology 2019, 54: 538-545. PMID: 31079556, DOI: 10.1080/00365521.2019.1594356.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsUpper GI symptomsRisk factorsGI symptomsCheckpoint inhibitorsGI inflammationAnti-PD-1/L1Non-steroidal anti-inflammatory drugsUpper GI injuryUpper GI toxicityGastrointestinal adverse eventsUpper gastrointestinal symptomsProton pump inhibitorsLower GI tractAnti-inflammatory drugsRate of ulcerationGI injuryICI initiationDuodenal involvementEndoscopic evidenceGastrointestinal symptomsGI toxicityImmunosuppressive therapyAdverse eventsGastric involvementVedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment
Tran C, Abu-Sbeih H, Luo W, Lu Y, Wang Y. Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment. Journal Of Immunotherapy And Precision Oncology 2019, 2: 40-45. DOI: 10.4103/jipo.jipo_18_18.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsLung cancerSteroid courseAdverse eventsAbstract Immune checkpoint inhibitorsUpper GI adverse eventsSignificant anti-tumor effectGI adverse eventsProgressive lung cancerUpper gastrointestinal injuryUpper GI toxicityAnti-tumor effectsNovel therapeutic classResolution of inflammationGI-irAEsHistologic remissionHistological remissionNivolumab treatmentVedolizumab treatmentCheckpoint inhibitorsClinical remissionGastrointestinal injuryGI toxicityPrednisone taperSevere nausea